Scarica l'app Stockscreener
2.98
4.93%
0.14
Genelux Corp Borsa (GNLX) Ultime notizie
Genelux (NASDAQ:GNLX) Raised to “Hold” at Wall Street Zen - Defense World
Two Sigma Investments LP Sells 18,446 Shares of Genelux Co. (NASDAQ:GNLX) - Defense World
Citadel Advisors LLC Lowers Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Millennium Management LLC Cuts Stake in Genelux Co. (NASDAQ:GNLX) - Defense World
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - Defense World
Genelux Co. (NASDAQ:GNLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Genelux (NASDAQ:GNLX) Trading Up 3.3% – Time to Buy? - Defense World
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Top Executives at Genelux Corp. Unload Thousands of Shares! - TipRanks
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView
Genelux Q3 EPS Raised by Brookline Capital Management - Defense World
HC Wainwright Issues Optimistic Outlook for Genelux Earnings - Defense World
Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position - TipRanks
Genelux (GNLX) Price Target Lowered by Benchmark Analyst | GNLX Stock News - GuruFocus
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating - TipRanks
H.C. Wainwright lifts Genelux stock target to $31, maintains buy By Investing.com - Investing.com Nigeria
H.C. Wainwright lifts Genelux stock target to $31, maintains buy - Investing.com
Genelux reports Q1 EPS (21c), consensus (24c) - TipRanks
Genelux (GNLX) Shows Strong Progress in Cancer Treatment Trials | GNLX Stock News - GuruFocus
Genelux Reports 71% Disease Control Rate in Lung Cancer Trial, Q1 2025 Earnings | GNLX Stock News - Stock Titan
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates - Yahoo Finance
Geode Capital Management LLC Has $716,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux CEO Discusses Next-Gen Immuno-Oncology Pipeline and Key Milestones at Citizens Conference - Stock Titan
LPL Financial LLC Has $222,000 Stock Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Raymond James Financial Inc. Takes $41,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Benchmark maintains $25 target on Genelux stock, optimistic on trials - Investing.com
Benchmark maintains $25 target on Genelux stock, optimistic on trials By Investing.com - Investing.com India
HC Wainwright Has Bearish Estimate for Genelux Q1 Earnings - The AM Reporter
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Analysts Offer Predictions for Genelux Q1 Earnings - Defense World
What is HC Wainwright’s Forecast for Genelux Q1 Earnings? - Defense World
Genelux (NASDAQ:GNLX) Given Buy Rating at HC Wainwright - Defense World
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements - TipRanks
H.C. Wainwright maintains Buy on Genelux shares, target at $30 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Genelux shares, target at $30 - Investing.com
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Brokers Set Expectations for Genelux FY2024 Earnings - Defense World
Research Analysts Set Expectations for Genelux Q1 Earnings - The AM Reporter
Genelux reports FY24 EPS (95c), consensus (88c) - TipRanks
FDA Green Light: Genelux's Cancer Drug Olvi-Vec Advances as 2024 Data Shows 71% Disease Control - Stock Titan
GENELUX Corp SEC 10-K Report - TradingView
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance
Genelux (GNLX) Projected to Post Quarterly Earnings on Friday - Defense World
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. - TipRanks
What is HC Wainwright’s Estimate for Genelux Q1 Earnings? - Defense World
Benchmark maintains $25 target on Genelux following trial data - Investing.com
Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Genelux stock holds Buy rating, $30 target from H.C. Wainwright - Investing.com India
Genelux prices 3M shares at $3.50 in underwritten public offering - TipRanks
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec - TipRanks
Genelux announces alignment with FDA of approval pathway for Olvi-Vec - TipRanks
Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial - MarketScreener
Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell - Nasdaq
Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study - Marketscreener.com
Genelux Prices $10.5 Million Stock Offering - MarketScreener
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock - GlobeNewswire
$10.5M Capital Raise: How Genelux Plans to Accelerate Cancer Drug Pipeline - Stock Titan
Breakthrough: Cancer Drug Achieves 79% Tumor Reduction in Advanced Lung Cancer Study - Stock Titan
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):